Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Deferred revenue by Quarter
Deferred revenue — Stand-ready manufacturing, collaborations & grants ($M) ($M)
Moderna Deferred revenue: $177M in Q2 2026, up 185.5% from a year earlier. That is the highest of the 8 quarters on record here.
Latest, Q2 2026
177
Period ended Jun 30, 2026
Change on a year earlier
+185.5%
62 in Q2 2025
History
8 quarters
Since Q2 2024
Sources
6
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 2 (Contract Liabilities).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Deferred revenue — Stand-ready manufacturing, collaborations & grants ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 177 | +185.5% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 161 | +455.2% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 145 | +530.4% | Form 10-Q (filed 2026-07-31) ↗ |
| Q3 2025 | Sep 30, 2025 | 176 | – | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 62 | +210.0% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 29 | – | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 23 | – | Form 10-K (filed 2026-02-20) ↗ |
| Q2 2024 | Jun 30, 2024 | 20 | – | Form 10-K (filed 2026-02-20) ↗ |
Cite this data
StockData. (2026). Moderna Deferred revenue ($M), quarterly Q2 2024–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/def-rev-other
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.